What happened
A federal appeals court let a big Tylenol lawsuit keep going. The case says the drug may be tied to autism and ADHD in children.
The ruling revived more than 500 private cases against Kenvue, Tylenol’s maker. A lower court had tossed them out after finding the expert proof too weak.
Who wins here
For now, the parents and lawyers get a second shot. That matters because a court door that looked shut is open again.
Kenvue also gets something, but not relief. It gets more years of legal fight, more cost, and more public doubt around a product many people trust.
How the play works
This fight is about expert proof. Judges did not say Tylenol causes autism. They said the lower court should not have barred the experts so fast.
That means the case can move forward on testimony, not just headlines. It also shows how a court ruling can reshape public debate, even when the science is still unsettled.
Why it matters
The public stake is bigger than one drug case. When science is still in dispute, court rules can give shaky claims new life.
That can push fear onto pregnant people, who must make fast health choices. It can also cost consumers through legal bills, product warnings, and more confusion about what is safe.
What to watch next
Kenvue said it will keep fighting the expert proof. That next round will matter more than the old dismissal did.
Watch for whether the case stays about evidence, or gets pulled deeper into politics. The court said this was not a political ruling. The public debate may not stay that neat.